Journal of Clinical and Aesthetic Dermatology

JUN 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/839245

Contents of this Issue

Navigation

Page 16 of 63

17 JCAD journal of clinical and aesthetic dermatology June 2017 • Volume 10 • Number 6 R Objective: Evaluate patients' p erceptions of rosacea symptoms and treatments. Design: Cross-sectional, web- based survey conducted from M ay 8 to July 1, 2015. Setting: E-mail invitation. Participants: Male and female adults in the United States who self-reported having a physician's diagnosis of rosacea. Measurements: Sociodemographic and clinical characteristics were collected for eligible respondents using the Self-Assessment of Rosacea Facial Redness scale and the Symptom Assessment for Rosacea Facial Bumps and Pimples questionnaire. Respondents were instructed how to differentiate erythematotelangiectatic rosacea and papulopustular rosacea. Use of different treatments and satisfaction with treatment were assessed, as were coping mechanisms. Results: More than 4,000 individuals responded and 600 completed the survey. The participants' mean age was 51.7 years and more than 90 percent rated their rosacea severity as mild or moderate. Most practiced stress and/or anxiety management, used makeup to cover rosacea, used sun protection, and changed their exercise regimens to cope with rosacea flare-ups. [Abstract continued on next page] A B S T R A C T O R I G I N A L R E S E A R C h The Burden of Illness of Erythematotelangiectatic Rosacea and Papulopustular Rosacea: Findings From a Web-based Survey a JAMES Q. DEL ROSSO, DO, FAOCD, FAAD; b EMIL A. TANGHETTI, MD; c HILARY E. BALDWIN, MD; d DAVID A. RODRIGUEZ, MD; e ILIA L. FERRUSI, PhD a JDR Dermatology Research/Thomas Dermatology, Las Vegas, Nevada; b The Center for Dermatology and Laser Surgery, Sacramento, California; c The Acne Treatment and Research Center, Morristown, New Jersey; d Dermatology Associates and Research, Coral Gables, Florida; e Allergan plc, Irvine, California ROSACEA, WHICH IS characterized primarily by persistent centrofacial erythema, affects an estimated 16 million adults in the United States. 1–3 The most common subtype is erythematotelangiectatic rosacea (ETR; subtype 1), characterized by persistent centrofacial erythema, intermittent bouts of vasodilation (flushing), and the presence of telangiectasia. 1,4 Papulopustular rosacea (PPR; subtype 2) is the second most common subtype, manifesting as transient, centrofacial papules or pustules. 1,4 The pathophysiology of rosacea is not fully understood, but data support the primary involvement of two Disclosure: This study was sponsored by Allergan plc, Dublin, Ireland. Manuscript preparation and editorial assistance was provided to the authors by Michael L. Pucci, PhD, of Peloton Advantage, Parsippany, New Jersey, and was funded by Allergan plc. Neither honoraria nor other form of compensation were made to the authors for authorship or any other activities related to preparation or submission of this manuscript. Related to the subject area of rosacea, Dr. Del Rosso serves as a consultant, speaker, and researcher for Allergan, Bayer Dermatology, and Galderma. Author correspondence: James Q. Del Rosso, DO; E-mail: jqdelrosso@yahoo.com

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - JUN 2017